340B Orphan Drug Solutions Founded by Dr. Lisa Nezneski, PharmD, BCPS, the firm brings over 40 years of healthcare expertise and more than 11 years of focused 340B orphan drug experience. Clients include Critical Access Hospitals, Rural Referral Centers, Sole Community Hospitals, and Free-Standing Cancer Hospitals affected by the October 2015 HRSA orphan drug exclusion ruling. 

The firm delivers customised orphan drug portfolios, split-billing software integration, quarterly designation and manufacturer discretionary pricing updates, job aids, and direct specialist access.